# **Emerging of Infectious Bronchitis Virus (renal mutant) Evading Chicken Vaccinal Immunity in Ismailia, Egypt**

El-Shahidy M.<sup>2</sup>, Neven Ramzy <sup>1</sup>, and Fetaih H.<sup>3</sup>

## <sup>1</sup>Institute of Animal Health Research, Dokki, Giza, Ismailia branch <sup>2</sup> Department of Virology and <sup>3</sup> Department of Pathology, Faculty of Vet. Medicine, Suez Canal University

Abstract: In spite of regular vaccination of chicken flocks in Egypt with Infectious Bronchitis Virus (IBV) vaccine, respiratory and kidney lesions had developed. Six vaccinated chicken flocks (5000/flock) in Ismailia, Egypt showed IB- like symptoms was screened for IBV isolation in SPF embryonated chicken eggs. Four Isolates of IBV were characterized and identified at the pathological, biological, physical and molecular level. IB virus spike (S1) gene was amplified by RT-PCR and sequence analysis of the hypervariable region of S1 gene using specific forward and reverse primers was done. Electrophoretic pattern of amplified S1 gene showed a specific band at 380 bp. IBV Ismailia isolates are clustered in distinct phylogenetic group with 4 recent IBV isolates circulating Egypt since 2012 (Egypt/12197B/2012, Eg/CU-2/2012. in Egypt/12120s/2012 and Egypt/01-13/VIR9715/2012). IBV Ismailia isolates showed 99.41%, 99.12%, 98.83 % and 98.54 % nucleotide sequence identity and 99.12 %, 100 %, 99.12% and 98.25% amino acid identity to the Egyptian IBV variants, respectively. In a conclusion, IBV Ismailia isolates are closely related to the recent Egyptian IBV isolates circulating in Egypt except minor changes in nucleotides and amino acids sequences. IBV Ismailia isolates are different from the currently IB virus strains used for vaccine production, indicating a constant evolution of IBV in Egypt. This difference necessitates continuous montoring to control the spread of infections and the development and use of vaccine should be based on indigenous viruses.

#### Introduction

IB is an acute and highly contagious respiratory disease of chickens characterized by high mortalities and severe respiratory distress in young chickens including gasping, coughing, sneezing, tracheal rales, and nasal discharge, moreover, decrease in egg production and loss of internal and shell quality of eggs in layers. It is one of the most important viral disease of chickens concerning the economic impact on

poultry industries (Sultan et al., 2004). IB caused by a virus belong to group 3 coronavirus (Cavanagh and nagi, 2003). It is an enveloped, positive non-segmented, sense ssRNA virus. IBV genome consists of 27 kb and codes for three structural proteins: the spike (S) glycoprotein, the membrane (M) glycoprotein, and the nucleocapsid phosphoprotein. (N) The S glycoprotein is composed of two glycopolypeptides: **S**1 and S2 (Cavanagh, 1983). Neutralizing and serotype-specific antibodies are directed against the **S**1 glycoprotein.

IBV has the ability to mutate or change its genetic makeup readily by point mutation or deletion or insertion or recombination. As a result, numerous serotypes have been emerged and escaped the vaccinal immunity (Meir et al, 2004; Abdel-Moneim et al, 2006). Several strains of infectious bronchitis virus have a strong affinity for the kidney causing severe renal damage and associated mortalities with high in chickens (Gorgyo et al, 1984). The affinity for kidney tissue may be resulted from mutation as a result of selection following pressure widespread prolonged use of modified live IB vaccines.

Controlling IB infection is difficult due to many factors e.g wide variations in the serotypes and virulence of strains that have developed from time to time, a highly contagious nature, and the evolution of specific tissue tropism and recombinants due to simultaneous infection of multiple virus types and use of live vaccines (Bayry et al, 2005). Outbreaks can occur in vaccinated flocks due to the lack of cross-protection against antigenically unrelated serotypes and variant strains of the virus (Gelb et al, 1991; Capua et al, 1994; Jia et al, 1995).

In spite of routine IBV vaccination in Egypt, outbreaks of IB frequently occur in the field due to the presence of different serotypes as well as the emergence of multiple subtypes. Accordingly, genotyping of IBV field strains is verv important for screening the emergence of new variants as well evaluating existing as the vaccination programs. In the current study, we present an analysis of the partial S1 gene sequences of IBV isolates from broiler chickens in Ismailia, Egypt to determine the cause of IBV vaccination failure and escaping the virus from vacccinal immunity. To achieve this were isolated goal. IBV and identified at the nucleotide and amino acid levels and compare them with the recent variant circulating in Egypt and other countries in the Middle East.

#### Material and methods 1- Broiler flocks

Six broiler chicken flocks of Cub breed (5000 bird each), 35-40 day old suffered of significant mortalities and respiratory and renal symptoms are included in this study. The flocks located in Abousoier, Ismailia governorate, which represent the eastern part of Egypt. The broiler flocks demonstrating a respiratory disorders, anorexia, and loss of bodyweight. possibly with associated increased mortalities. Mortality rates ranged from 15 to 30 %. Postmortem petecheal findings included hemorrhages in the larynx and trachea, and severe congestion and urates deposition in the kidneys and ureters.

## 2- Samples

Five bird of each flock were collected for virus isolation and post mortem examination. A part of kidney, lung, trachea, bronchi and liver of each bird are pooled and aseptically transferred in transportation media for virus isolation. Another parts of previous organs are kept in 10% formalin for histopathological examination and the third parts of organs kept frozen for PCR assay.

#### 3- Virus isolation

Virus isolation was carried out according to the method described by Momayez et al (2002). Briefly, pooled samples were homogenized to give approximately 10% (w/v) suspension PBS pН 7.2 in containing 100IU/ml penicillin, 100µg/ml streptomycin, and 30 IU amphotericin B/ml. The homogenized samples were centrifuged at 1000g for 15min at 4°C and then filtered through a 0.45µm filter membrane. The

supernatant was inoculated at 0.2ml via the allantoic cavity of groups of ten 9-11 day-old SPF eggs.

Inoculated eggs were checked twice a day. Those that died within 24h after inoculation were discarded. Mortality between 2 and 7 days post inoculation (PI) were considered to be virus specific. The allantoic fluid was harvested aseptically from embryos that died between 48 and 72h PI, if the fluid showed no Hemaglutination (HA) activity. Dead embryos were examined for the presence of embryo stunting, curling, urates in the mesonephros, or focal necrosis in the liver. On day 3 PI, part of the eggs were removed from the incubator and were placed at 4°C for 24h and the allantoic fluid was collected for the next passage.

## 4- Viral RNA extraction

Viral RNA was extracted from infected allantoic fluid of the third egg passage and from clinical pooled samples using a DNA/RNA extraction kit (QIAamp minikit, Qiagen, Germany) as recommended by the supplier.

## 5-RT-PCR

RT- PCR was used to amplify the S1 gene of IBV using Qiagen one step according test Kit to manufacturer's instructions. The mix per one reaction are; 25 µl of 2x RT-PCR buffer, 1 µl of each Forward and Reverse primers, 1 µl of RT-enzyme, 1 µl of MgSO4, 11 µl of RNase-free water and 10µl of Template RNA in 50 µl Total volume using thermal cycler

The sequence and length of the primers used for amplification of S1 gene of IBV are designed according to Adzhar et al., (1997). Sequence of foreward and reverse primers are **IBV-S1-F** (5'-CACTGGTAATTTTTCAGATGG

-3') and **IBV-S1-R** (5'-CAGATTGCTTACAACCACC-3')

#### 6-Agarose Gel Electrophoresis

RT-PCR products were loaded in agarose gel and covered with electrolyte solution in 1X TBE and allowing running the PCR product in the gel at 95 V for 40 minute, to determine the base pairs of the PCR product (380 bp) which could be visualized compared to 100 bp ladder (Qiagen, Germany) using Gel documentation system (Biometra, Germany).

#### 7-Phylogenetic analysis

The **RT-PCR** product were separated purified and using purification kits (Fermentas Inc., Ontario, Canada) according to the manufacturers protocol. Purified RT-PCR products were sequenced in forward and reverse directions. Sequencing reaction was performed Prism with the ABI BigDye Sequencing Terminator Cycle Ready Reaction Kit (Applied Biosystems, USA) as described by the manufacturer in an ABI Prism310 Genetic Analvzer (Applied Biosystems, USA).

Sequence of S1 gene of Ismailia IBV isolates were compared with the IBV sequences in GenBank database using a BLAST search via the National Center of Biotechnology Information (USA), and sequence similarities were included in alignment and phylogenetic construction. The phylogenetic tree was constructed by Unweighted Pair Group Method using Arithmetic averages (UPGMA) together with a bootstrap analysis. The analysis was carried out in Mega 6 program.

The S1 gene sequences of other previously IBV retrieved in the GenBank in this study are: Eg/12197B/2012(Acc

U (	
no.KC533683),	Eg/CU-2/2012
( <u>KC985213</u> ),	Eg/12120s/2012
( <u>KC533684</u> ),	Egypt/01-
13/VIR9715/2012	( <u>KC527831</u> ),
<b>RF/06/2008</b>	(HQ840489),
<b>RF/07/2008</b>	(HQ840490),
UK/142/86 (X580	<u>)66</u> ), UK/123/82
(X58067), IS/589/	<b>98</b> ( <u>AY789963</u> ),
IS/572/98 (AY78	<u>9961</u> ), <b>IS/1366-</b>
Sp1 (Acc no.EU3	<u>50550</u> ), <b>IS/236-</b>
S1 (Acc no. <u>AY</u>	<u>135205</u> ), <b>IS-</b>
1494 (Acc	no. <u>HM131453</u> ),
H120 (Acc	
no.JN600610), Ma	5 (Acc

no.AY561713), Connecticut (Acc

no.<u>AF094818</u>), **4/91** (Acc

no.<u>AF093794</u>) and **D41** (Acc no.<u>AF036937</u>).

#### 8- Histopathology

The collected samples from kidneys, trachea, lung and liver were fixed in 10% neutral buffered formalin for 24 hours. The samples

were then washed, dehydrated in ethyl alcohol, cleared in xylene and embedded in paraffin wax, as routinely allowed. Histological sections at 4 -5 microns from embedded samples were done and stained with the routine stain, hematoxylin and eosin (Luna, 1988).

### Results and discussions 1- Gross necropsy findings

All birds examined for post mortem findings showed similar pictures. The most frequent finding was mucosal thickening with serous or catarrhal exudates in the nasal passage, trachea, bronchi and air sacs. Respiratory tract was partially or completely blocked with dry, caseous yellow casts results in high pitched cheeping and may be the main cause of death. Pneumonia, conjunctivitis and swollen sinuses were also seen.

The kidneys were dark, congested, swollen and showed petecheal hemorrhages and urates deposition (Fig. 1). Ureters were hyperemic, congested and showed urates deposition. Liver. bursa of fabricious and spleen were congested, swollen and showed pinpoint hemorrhages in subserosal surfaces.

Respiratory system is the main site of IBV multiplication, following which viremia occurs and the virus become widely distributed in the body particularly kidneys and reproductive system (Darbyshire, 1981). In kidneys, the virus probably occurs in epithelial cells lining the ducts and tubules produce marked swelling and hemorrhages in kidney tissues in an acute form (Duff et al., 1971) and possibly also in a chronic form (Alexander et al., 1978).

## 2- Virus isolation

After the third passage of six IBV isolates in specific-pathogen-free embryonated eggs, lesions were observed in the form of mortality of embryos, stunting, curling (Fig.2), and uric acid deposition in the kidneys and ureter. The results obtained in (Fig.2) were in accordance with that obtained by Susan and El-Hady (2010) and DeWit et al. (2011). The allantoic fluid of inoculated eggs were found to be negative for Newcastle disease virus and avian influenza virus by Hemaglutination assay.

The isolate recovered from kidney of the IB vaccinated flock was shown to produce dwarfing of the embryos infected and showed similar characteristics of coronavirus IBV. The clinical manifestations, gross and microscopic lesions of the infected chickens were the same as those nephropathogenic infected with IBVs (Calnek, 1997; Zhou and He 2000).

#### **3-Histopathological finding:**

Histopathology can be useful in studying of IBV virulence and pathogenesis, and help in diagnosis of acute and non-complicated IB. The respiratory tract showed severe acute hemorrhagic tracheitis and

pneumonia. The changes in trachea included: edema, desquamation of epithelium. mononuclear cell infiltration of the submucosa and severe congestion and hemorrhages of the trachea (Fig. 3). The lung suffered also from interstitial pneumonia (Fig. 4). The reaction of trachea and lung are extensively studied and well described by Purcell and McFerran (1972).

The prominent histopathological change in the liver was focal infiltrations of the hepatic tissues mononuclear inflammatory with cells and some heterophils. In the kidnevs. severe congestion. hemorrhages and necrosis of the tubular epithelium were seen. Focal infiltrations of the interstitial tissue with lymphocytes was seen between urinary tubules. Signs the of regeneration of the tubular epithelium could he seen. Hyperplasia of the glomerular epithelium was also an evident finding (Fig. 5, 6 and 7).

IBV strains isolated from Ismailia are nephropathogenic and replicate in respiratory tissues and kidney, but the lesions are more evident in the kidney. Several reports confirmed the tropism of IBV to Kidney tissues (Purcell et a., 1976; Albassam et al, 1986; Ignjatovic et al, 2002; Lee et al, 2004; Benveda et al, 2009, 2010; Boroomand et al, 2012). The tubular epithelial cells of the kidney are the target cells of IBV (Owen et al., 1991; Janse et al., 4-RT-PCR

Four IBV isolates out of six isolates RT-PCR were positive in Amplification of the S1 gene from the infected allanotic fluids and pooled clinical samples resulted in a 380 bp amplicon as shown in Fig. 2 (didn't not appear with the uninfected allantoic fluid as a The positive negative control). results were seen with  $10^{-2}$  to  $10^{-5}$ dilutions of allantoic fluid. Further dilutions could not yield any PCR products. No amplifications were seen when using primers for NDV, AI and IBD viruses.

A primer pair forward and reverse was used in this study to detect IBV by S1 gene amplification in clinical samples and in allantoic fluid of infected eggs. It was showed that the primer can amplify 380 bp of S1 gene (Fig. 8). These results shown to be the same as obtained by Peyman et al (2013) and Susan El-Hady (2010). The primers was designed specific to a conserved region of S1 gene to ensure a wide detection range. PCR amplification of S1 gene: was applied for the first 1230 base of S1 gene which contains the 3 hyper variable regions (HVRs) of S gene (Dolz et al, 2006; Cavanagh et al, 2005).

# 5-Phyogenetic analysis of S1 gene of IBV Ismailia strain

342 nucleotide sites in hyper variable region (HVR) of the S1 gene of IBV, Ismailia strain was characterized for the whole dataset and compared with the IBV sequences in GenBank database using BLAST search via the National Center of Biotechnology Information (USA). BLAST analysis revealed that, IBV-isolate-Ismailia-Egy/2014 is shared significant similarity the at nucleotide level with other IBV Egyptian isolates emerged in 2012 Egypt/12197B/2012, Eg/CUas 2/2012. Egypt/12120s/2012 and Egypt/01-13/VIR9715/2012 with of identity percentage 99.41%, 99.12%, 98.83% and 98.54% respectively.

This isolate also found to be different from other Egyptian IBV vaccinal strains as H120, Ma5, Connecticut and **D41** with a lower percent of identity 38.60%. 72.22%, 47.36% and 71.93% respectively as showed in figure (9) and table (1). IBV-Ismailia-isolate had less similarities when compared with IBV Israeli (IS/1494, IS/589/98. strains IS/572/98. IS/1236-Sp1 and IS/236-S1) with an identity percent 88.60%, 88.60%, 86.84% 76.90% and 72.51% respectively (Fig.12 and table 1).

Deduced amino acid sequence of S1 of Ismailia isolate IBV demonstrated high similarity and little variations when compared with other recent IBV Egyptian 2012 isolates emerged in as Eg/12197B/2012, Eg/CU-2/2012, Eg/12120s/2012 and Egypt/01acid 13/VIR9715/2012. Amino sequences of IBV Ismalia isolate was found to be closely related to Eg/CU-2/2012 with identity percentage of 100%. Only one

amino acid substitution at site 75 from A to S (A75S) and at site 56 from N to H was found with Eg/12197B/2012 and Eg/12120s/2012 respectively. Two amino acid substitution were found in Egypt/01-13/VIR9715/2012 at site 67 and 44 (S67I and S44V). Low similarity and wide variations between Ismailia isolate and other IBV vaccinal strains as H120, Ma5, Connecticut and D41 with variations in 94, 38, 92, 26 and 38 amino acids.

Deduced amino acid sequence of S1gene of IBV Ismailia isolate in comparison with IS/1494, IS/589/98, IS/572/98, IS/1236-Sp1 and IS/236-S1 revealed wide divergence in 15,13, 13, 28 and 38 amino acids.

The low nucleotide and amino acid similarities between IBV vaccine strains and Ismailia isolate may account for the occurrence of the IBV outbreak in vaccinated flocks. Production of a new vaccine based on the Egyptian genotype is necessary to protect the poultry industry in Egypt.

Phylogenetic analysis of recent Egyptian IBV isolates revealed that the sequences of S1 gene of blasted IBV strains formed two main distinct groups (Fig. 11). The first group subdivided into three subgroups: group A, including recent Egyptian IBV (IBV isolate Ismailia, Eg/12197B/2012, Eg/CU-2/2012. Eg/12120s/2012 and Egypt/01-13/VIR9715/2012). The subgroup B including: European IBV sequences (UK/123/82, **RF/07/2008**, **RF/06/2008** and UK/142/86), the subgroup С including: IBV Israeli sequences (IS/589/98, IS/572/98 and IS/1494/06). The second group including: IBV vaccinal strain and Israeli sequence sequences (IS/236, Ma5 and D41).

It is known that theS1 subunit was involved with infectivity of IBV carries serotype-specific and sequences (Cavanagh and Davis, 1986: Cavanagh 1995) and antigenic epitopes inducing virus neutralizing antibody. The different serotypes, subtypes or variants of IBV was thought to be generated by nucleotide point mutations. insertions. deletions or **RNA** recombinations of **S**1 genes (Cavanagh 1983; Cavanagh and Davis, 1986; Jia et al., 1995), which responsible were for outbreaks of IB in the vaccinated chicken flocks. In addition to serotype changes, the genetic variation may result in changes of the tissue tropism and pathogenicity of the virus, which lead to the generation of new IBV pathotypes.

The genetic diversity of IBV strains arises primarily by mutations, which are induced both by the high error rate and limited proofreading capability of the viral RNAdependent **RNA-polymerase** and by recombination (Jackwood et 2012). al.. The **S**1 protein commonly differs by 20 to 25 % of the amino acids among different IBV serotypes (Keeler et al., 1998 and Kingham et al., 2000): however, some IBV serotypes show as little as 2 % differences in S1 (Cavanagh et al., 1992). The antigenic sites in the amino acid sequence of the spike sequence were determined (Kant et al., 1992).Three HVRs are located within residues of 38-67, 91-141 and 274-387(Cavanagh et al., 1988, Koch et al., 1990 and Moore et al., 1997).

Multiple sequence alignment and phylogenetic tree analysis separate IBV isolates into different groups which are genotypically related to each other. Most of the serotypes are different from each other in the first HVR of S1 spike glycoprotein. This region seems to be conserved in each geographically isolated virus, which can be used for genotyping of the virus. It is most likely that this region is a serotype specific determinants of IBV and contains antigenic epitope, which is serologically important for serotyping of IBV (Abdel Moniem et al., 2012).



**Fig 1:** *Kidneys and ureters of chicken showed swelling, congestion and petechial hemorrhages in the surface.* 



Fig 2: Stunting and curling of chicken embryos inoculated with IBV (arrow: control)



Fig 3: Tracheal mucosa and submucosa showing severe congestion with hemorrhages, necrosis and loss of surface epithelium and leukocytic infiltrations in the lamina propria. H&E. X200



**Fig 4:** Lung tissue showing severe congestion and heavy infiltration of the interalveolar septa with heterophils and lymphocytes. The alveolar lumina either collapsed or contain inflammatory exudate. H&E. X200



**Fig 5:** *Histopathological picture of the kidney showing focal infiltration of the interstitial tissue with inflammatory cells, and degeneration of the tubular epithelium. H&E. X200.* 



Fig 6: Histopathological picture of the kidney showing severe congestion of the intertubular blood vessels. H&E. X200.



**Fig 7:** *Histopathological picture of the kidney showing hypercellularity of the glomeruli and degenerative changes of the renal tubules. H&E. X200.* 



Fig 8: *RT-PCR* results for *IBV–S1* gene: Lane 1: Postive control, Lanes 2-5: Positive IB samples, Lane N: Negative control.

	1									10									20										20										40						
	1									10									20	·									50										+0						
Name	A	A	G	A	A	Т	Т	Т	С	A	G	1	G (	1	0	; C	E T	00	C C	T	G	Т	G	G	С	Т	A	Т	G	A	5 A	G	C	A	С	C	T	C	A	A	A A		G	G	Т
1. IBV isolate Ismailia Egy/2014																																													
2. IBV isolate Eg/12197B/2012																																													
3. IBV isolate CU-2	J.																																												
4. IBV isolate Eg/12120s/2012																																													
5. IBV/Egypt/01-13/VIR9715/2012																																													
6. IBV isolate RF/06/2008																				C																			G						
7. IBV isolate RF/07/2008																				¢																									
8. IBV virus (IBV) (UK/142/86)																				C																									
9. IBV (UK/123/82)																				C																									
10. IBV strain IS/589/98			А						Т					. A	1								А			C												G	G	Т	. Ç	) A	ι.		
11. IBV strain IS/572/98			А						Т					. A	1	١.							А			С												G	G	Т	, ¢	) A	ι.		
12. IBV isolate IS/1366	С		т						Т	Т	С					T	۰.						А			С							Т				Α	т		Т					
13. IBV isolate IS/236	С	G	Т	G	Т		G		Т		A				. 1						A		А								. 0	١.					G	Т	С	. 1	τс	) A	ι.		
14. IBV isolate IS/1494/06			А						Т					. A	1								А			С												G		Т	. Ç	) A	ι.		
15. IBV strain H120			т		G		G		Т		A	. 1	A.		1	١.			T		Α	С		Т	Т	С		С	А		ГТ	Т				Т	Α	т		. 1	ΤĢ	3 A	ι.	Α	С
16. IBV strain Ma5	С	G	т	G	Т		G		Т		A				. 1	١.					A		А								. 0	١.					G	Т	С	. 1	τс	) A	ι.		
17. IBV strain Connecticut 46		Т		G	G	С	С		G	Т	Т			. 0	5 /	١.	A	١.							Т	Α			Α	G	r (	т	Т	G	G	Т						A	ι.	Α	
18. IBV strain 4/91	T		Т				A		Т	Т	С												А			С							Т				А		С	T (	GC	۶.			
19. IBV strain D41	С	G	Т	G	Т		G		Т		A				. 1	١.					A		А								. 0	١.					G	Т	С	. 1	τс	) A	ι.		

		5	0							6	0							70							80	)							90	)			
Name	A	G	T	C	A	T	3 G	T	C	A A	C	TI	T C	A	G	A A	T	т	ТТ	G	T/	A C	G	GC	ΣT	C	A	Т	G	C	A	T	T	T	T A	C	T
1. IBV isolate Ismailia Egy/2014																																					
2. IBV isolate Eg/12197B/2012																																					
3. IBV isolate CU-2																																					
4. IBV isolate Eg/12120s/2012								-										-					-														-
5. IBV/Egypt/01-13/VIR9715/2012	2 .																																				
6. IBV isolate RF/06/2008									. 1	Τ.		. (	C A	G	С																						
7. IBV isolate RF/07/2008										Τ.		. 1	A A	Т	С																						
8. IBV virus (IBV) (UK/142/86)										Τ.		. (	C A	G																							
9. IBV (UK/123/82)				Т						Τ.		. (	З.	G	С																						
10. IBV strain IS/589/98					Т							C,	A A		С	. 0	З.		С.											т		С					А
11. IBV strain IS/572/98				÷	Т							C,	A A		С	. 0	Э.		С.											Т		С					А
12. IBV isolate IS/1366					T					. G	Т	1		2	С								A				. 1	Γ.		Т		С		. (	СТ		A
13. IBV isolate IS/236			G		Т					Τ.	G	C	A G	Т	С	. 0	÷.						Т		A	Т				Т		C			. т		A
14. IBV isolate IS/1494/06	1.1		1	1	T	5		1		. G		C	A G	C	C	. 9	3.		с.				5	1		:			2	Т		C	5				A
15. IBV strain H120	TO	3.	C	G	c	C /	A A	С	1	с.	A	A		ç	T	. 0	3.	G	G.				C	A G	5 A	A	T A	Α.	Т	2		A	Ç		1		c
16. IBV strain Ma5			G	÷	T				2	Τ.	G	C /	A G	T	C	. 0	÷.	÷					Ţ	: :	A	Т				Ţ		C			. 1	:	A
17. IBV strain Connecticut 46			G	A	2	C			1		A		. 1	C	1			C		C				A A	A		C /	<u>.</u>	C	5	G	; C		۰.		A	:
18. IBV strain 4/91					÷					. G				÷	C	. 0	ž.						A		1	÷				÷		C		. (	51		A
19. IBV strain U41			G	1	. '						A	C,	4 6	1	C		5.						1		A					1		C	1	1	1		А
				100	)						110							1	20						1	30								140			
Name	G /	A T	T	Т	Т	G	ΓA	G	Т	A T	Т	T	GΤ	Т	A	C /	A C	Α	ΤI	G	T	ΤA	Т	A	A A	T	C	ΤG	G	Т	T	C A	T	G	Τ (	СС	Т
1. IBV isolate Ismailia Egy/2014																																					
2. IBV isolate Eg/1219/B/2012																																					
3. IBV isolate CU-2 4. IBV isolate Ex/12120c/2012																														ċ							
<ol> <li>BVEount/01,13/JR9715/2012</li> </ol>																										Ġ	Ť			0							
6. IBV isolate RF/06/2008																					ċ					č	Å										
7. IBV isolate RF/07/2008																					č					č	A										
8. IBV virus (IBV) (UK/142/86)																					С					С	A					τс					
9. IBV (UK/123/82)																					С																
10. IBV strain IS/589/98						A I	с.			G.													С														
11. IBV strain IS/572/98						A I	с.			G.													С														
12. IBV isolate IS/1366		. C	1			A	C .			G.		С				. (	3.					. т				c	A (	с.	÷		A	GC					
13. IBV Isolate IS/236 44. IBV isolate IS/404/08			A	Ç		A				G.													ċ			c	A		1		G	5 6			1		
14. IDV ISUBIE IS/ 1494/00 15. IDV strain U120	1		ċ	Å	ċ	~		ċ	Å	с. с.		ċ	 	Å	c ·	т (	2	Ġ		Å			0		÷	0	т		÷.		٠,	· ·		ċ	è i	г. т.т	
16. IBV strain Ma5	^		Ă	ĉ	č	A	6	č	^	G		~		0	0			0		^						ċ	Å		0		Ġ	s G		0	0		
17. IBV strain Connecticut 46	A	G		Ţ		т				. A	Ľ.	ċ	τ.	Å	G			G	c e	Â		Ť					т	÷τ				G .	ċ	A	ċ	Ť	ċ
18. IBV strain 4/91		. c				A	с.			G.						. (	З.					. т				С	A	Α.			A	GТ					Α
19. IBV strain D41			A	¢		A	с.			G.																С	A	G.			G	GG					
				1	50						16	0							170							18	0							190	)		
Name	ТТ	A	A	Č	A	G	T	A	Т	3 A	T	T	: 0	A	C	A (	A	A	TIT	A	T	A T	Т	C (	G T	A	T	ТТ	C	Т	G	СT	A	T	G	A G	A
1. IBV isolate Ismailia Egy/2014																																					
2. IBV isolate Eg/12197B/2012					2									1																1	1				1		
3. IBV isolate CU-2																																					
4. IBV isolate Eg/12120s/2012																	C																				
5. IBV/Egypt/01-13/VIR9715/2012																																					
6. IBV isolate RF/06/2008								С																												. A	١.
7. IBV isolate RF/07/2008								С											. C																	. A	ι.
8. IBV virus (IBV) (UK/142/86)								С																												. A	
9. IBV (UK/123/82)								С									Т		. C																	. A	
10. IBV strain IS/589/98								т											. C																	. A	
11. IBV strain IS/572/98								Т						2					. C																	. A	
12. IBV isolate IS/1366		G			G		ċ			1			1	T			C		. C	÷			÷			÷											
13. IBV ISOIATE IS/236	Α.				1		C	ċ		. C			. A				C			C			A			G										· ^	
14. IBV ISOIBLE IS/1494/00 15. IBV strain H120	c ·	ċ		ė	÷.			T	۰.	r e		۰.	r A	ċ	÷	6 1				Ť			Ġ	÷	Δ.	Ġ	ġ.	Δ.			÷	Δ.	ċ	Å	ċ	. A C C	
16 IRV strain Ma5	Ă.	0		0	ť		ċ	1		0				0		<i>.</i>	ċ			ċ			A			å	9	n .			1	n .	0	A	v		
17. IBV strain Connecticut 48	c	1		Ġ	÷.	Ă.	~		ċ	r v	ċ		G	Ġ	1	s c	τ	ċ		Ť			~	Ġ	ΑA	G	Å	Ì	Ť		÷.	TA	Ť		÷.	16	
18. IBV strain 4/91		G	1	ĩ	1			1	Ĩ		Ĩ			Ť	. '			Ĩ.	Ċ				÷	. '		,				1	1			1	1		
19. IBV strain D41	Α.				т		¢			c			A	1			c			c			A			G										Ā	

# SCVMJ, XX (1) 2015

						200	)					21	0						2	20							23	0						24(	0		
Name	A	A	ΤA	A	Т	Α	G	TT	Т	GI	Т	Т	T.	A T	A	A	TI	Т	A	A (	C A	G	T	ΤG	C	T	ЗT	G	A	C T	Γ A	A	A	ΤA	Т	TO	СТ
1. IBV isolate Ismailia Egy/2014 2. IBV isolate Eg/12197B/2012									•															 T											-		
2. IDV Isolate Cyre for breate																								1													
A IBV isolate Ea/12120e/2012																																					
<ul> <li>E IDV/Equet/01.12/JID0716/2012</li> </ul>							÷																														
6. IDVIEgypro11131416911312012 8. IDV. isolate DE/08/2009					ċ												<u> </u>				• •															ċ	
7 IBV isolate PE/07/2009				. 0	č												č.																			č	
9 IDV views (IDV) (116/14/2000				6	č												č .																			č	
0. IDV VIUS (IDV) (UIV 142/00)				6	č												c.																			č	
0. IDV (01V123102) 10. IDV atrain IC/E00/00				0	č												č .																			č	
10. IDV strain ID/500/00				6	č												č .																			č	
12 IRV isolate IS/1366	Ġ		6	1 6	Ă	Ġ	÷.										č.								Ġ			Å	÷							č	
12. IDV Isolate IS/1300	0		. 0	10	2	č				÷							· .								G			2	ċ				c.		ċ	č	
13. IDV Isolate IS/1404/06			. 0	0	č	0	~ `	0 0		1							è								0			~	0				0		0	č	6
14. IDV Isolate IS/1454/00		ċ	14	1 0	v							÷.	à		÷		с. с.				÷.,			1		· .		÷	ċ	<u>,</u>	1÷	÷	ċ	6	à	۷,	÷
16 IBV strain Ma5		0	6	1 6	ċ	ċ	2	a c		÷		2	0				0 /					~			G				G	· ·		1	G	. 0	č	ċ	
17 IBV strain Connecticut 48		ċ		. т	~	·	2	~ ~				č	c.		÷								Å		~			÷	Ť				۲.		č	č.,	
12 IBV strain 401	÷	č		2 0	à	÷	÷.					0	0				00						~		6	2			÷	~ ·					č	÷.	30
10. IBV strain D41	Ľ.,	0		10	6	ċ		a c		÷												÷	ċ		G	0		2	å				Ġ		č	č	
18. IDV Strain D41			. 0	10	2	250	~ `	00					2	60							27	'o'	0		0			^;	280				0		Ū	0	
Name	A	G	AT	ΓT	Т	A	A (	GΤ	C	GC	Т	Т	C	A G	Т	G	ΤG	Т	Т	A	A T	A	A.	ΤA	Т	G /	I C	Α	ΤI	СТ	G	Т	G 1	ΤA	Т	C	A
1. IBV isolate Ismailia Egy/2014																																					
2. IBV isolate Eg/12197B/2012																																			С		
3. IBV isolate CU-2																																			С		
4. IBV isolate Eg/12120s/2012																																			С		
5. IBV/Egypt/01-13/VIR9715/2012																																			С		
6. IBV isolate RF/06/2008																																	A		С		
7. IBV isolate RF/07/2008																																	A		С		
8. IBV virus (IBV) (UK/142/86)																																	A		С		
9. IBV (UK/123/82)																																	A		C		
10. IBV strain IS/589/98																								·									A .		0		
11. IBV strain IS/572/98							•			1.		ċ		1						1				·	ċ	÷							A .		C	2	
12. IBV ISOIBLE IS/1300 13. IBV/ isolate IS/238		ċ	÷				- 1	а а ^		14		U								. (	3 0			·	U					12	1		~			ч т	
13. IBV Isolate IS/230 14. IBV isolate IS/1404/06		0					. /	A .		A 1																A .			ċ				Å .		è	÷	
15 IBV strain H120		Å	Ť	ċ	Â	ċ	÷.	Ť		À			÷,	ċ à	Å	÷		ċ		Ť	ċ	å	å	ċ	ċ	÷ é			6	ġ.		Ġ	÷.	G	č		Å Å
16 IBV strain Ma5		ĉ	÷.			·	1	Δ.		ÂÌ	r .											0	0	. т	~	à			· ·	č		0	Δ.			÷ í	
17. IBV strain Connecticut 46		č	тс	a c	Â	Ġ	G	A C		Ť.			Å	G .	ċ	Ť.	Ċ	ċċ		Ť	A	Ġ	Ġ	A C	ċ	T C	3	G		Ġ.		ċ	TO	c g		G /	A .
18. IBV strain 4/91		Ă						Α.		÷ .				Ā						G	s c			. т	č	Ť.							ċ			T	
19. IBV strain D41		С	τ.					Α.		À 1	Γ.													. т		A				. c	5.		A			т	
			300	0						3	10							32	0						33	30							34	0			
Name A A T G G	C	G A	τ	С	T	ΤC	Τ	G	ΤT	T	A (	СT	Τ.	CI	I A	A	TG	A	τ.	A C	ΞT	C	A_A	G	A_T	G	Τ.	ΤA	G	T	GC	A 🤇	G	C A	G	G 1	(
1. IBV isolate Ism																																					
2. IBV isolate Eg/										ċ																											
A IBV isolate Eo/ C										0																											
5. IBV/Egypt/01-1 C														2.1			2.2		2			2															
6. IBV isolate RF/					. (	с.		т									с.		G			А										т					
7. IBV isolate RF/					. (	с.		Т									с.		G			А										T					
8. IBV virus (IBV)					. (	С.		Т									С.		G			А										T					
9. IBV (UK/123/82					. (	C.		т									с.		G			А										T					
10. IBV strain IS/E	Ţ					с.		Ţ														A															
12 IBV strain IS/C	Ť					. v		÷		ċ									è			A T	i i	÷	1				ċ	ċ	1	÷ T				17	
13. IBV isolate IS/	÷							÷	A	č		c							G		ċ	Å	č '	1					č	Ă	T	Ť					
14. IBV isolate IS/	Ť				1	c .		Ť		ĩ			1						ĩ		ĩ	A							Ĭ	2							
15. IBV strain H12 C . A T C	Т	. i	r c	т			G	т	C A	A	с		G	т	G	т	Â	Ť	G	ст		A	ст	c		A	. (	GG	A	G	. 1	r c	C	ΤТ	т		5
16. IBV strain Mat	Т							т	. A	С		C						С	G		С	A (	с.						С	A	Τ.	Т					
17. IBV strain Cor T A A	Т	. 0	i C					т		G	C.	. C	С			т	. A	T	А		Α	G	С.		. A	A	. (	GC	A	A .	Α.	С	Т	ΤG	Т	A .	
18. IBV strain 4/9	Ţ							Т		C									A		Α	A	с т	С	. C				С	G	. 0	Τ				. 0	2
19. IBV strain D41	T							Т	. A	C		C							G		C	Α (	C.						C	A	Ť,	T					1

39

								30(	0								31(	0								32	20								3	30									34(	0			
Name	A	A	T (	3 (	C	G	A	Т	С	T	T	G	T	G 1		T	A	C	T	T	C	T	A.	A	T (	G A	T	A	C	T	C	A	A	G /	A T	0	Τ	Т	A	G	Т	G	C	A	G	C A	G	G	Т
1. IBV isolate Ism																																																	
2. IBV isolate Eg																																																	
3. IBV isolate CU		. (	С													С																																	
4. IBV isolate Egi	١.	. (	С																																														
5. IBV/Egypt/01-1		. 1	С																																														
6. IBV isolate RF	١.										С		. 1	T.										. 1	С		G				А													Т					
7. IBV isolate RF	١.										С		. 1	T.										. 1	С		G				А													Т					
8. IBV virus (IBV)											С			τ.										. 1	С		G				А													Т					
9. IBV (UK/123/8	١.										С			T.										. 1	Ċ		G				A													Т					
10. IBV strain IS/					Т						С			т																	A																		
11, IBV strain IS/					Т						C			т																	A																		
12. IBV isolate IS					Т									Т		C											A				т	С	Т	Т	. (					С	G		G	Т					С
13. IBV isolate IS	١.				Т									Τ.	. /	C			Ċ								G			Ċ	A	С								Ċ	A	Т		Т					
14. IBV isolate IS	١.				Т						С			Т																	A																		
15. IBV strain H1	c		A	го	: т		Т	С	Т			A	G	T (	; /	A	С			G	т		G	т		A T	G	С	Т		A	c	T	С		A		G	G	A	G		Т	C /	C 7	ТТ	Т		С
16. IBV strain Ma					Т									Т	1	C			С							. 0	; G			С	A	С								С	A	Т		Т					
17. IBV strain Co	т			A A	T		G	C						Т		G	C		C	С				т		A T	A			A	G	С			1			G	C	A	A	A		C '	T 7	T C	τ	A	
18. IBV strain 4/9					Т					÷			Ŀ	т		Ċ											A			A	Ă	C ·	Ť (	ċ	. (					Ċ	G		G	T					ċ
19. IBV strain D4	Ľ				Т		÷			ĵ.				т	1	c	1		Ċ	ĺ.	Ĩ.	Ĩ.					G		1	C	A	Ċ								ć	A	Т		Т					Í.
E' 0			7	τ		1		<i>.</i> .	. ,											Ĩ.,	c	1	· . ,	r					$\overline{r}$	, T		-				7	ה	$\mathbf{v}$	-	1		Ϊ.							
F1g 93			I۷	U	C	le	0	τı	d	е	1	se	q	U	eı	10	ce	S	(	)J	-	d	IJ	Ţθ	2r	e	nt		E	g.	<i>V</i> ]	pt	10	lľ	l	1	В	V		V	a	rı	a	nt		Sl	r	aı	ns

compared with Egyptian and Israeli variants. The horizontal line represents the sequence limits of HVR-3. Dots indicate identical sequences.

										10									1	20										30									4	10
Name	K	N	F	S	A	A	S	۷	Α	М	т	А	Ρ	Q	Ν	G	М	S	W	s	т	s	Е	F	С	т	Α	н	С	N	F	Т	D	F	۷	۷	F	۷	т	н
1. IBV isolate Ismailia Egy/2014	١.																																							
2. IBV isolate Eg/12197B/2012	١.																																							
3. IBV isolate CU-2	١.																																							
4. IBV isolate Eg/12120s/2012	1.																									2														
5. IBV/Egypt/01-13/VIR9715/2012	2																																							
6. IBV isolate RF/06/2008	١.													R								Q	Q																	
7. IBV isolate RF/07/2008	1.																					Ν	Q																	
8. IBV virus (IBV) (UK/142/86)	1.																					Q																		
9. IBV (UK/123/82)	1.																	L				А	Q																	
10. IBV strain IS/589/98	1.					s								G	т							к	Q												т					
11. IBV strain IS/572/98	1.					S								G	т							к	Q												т					
12. IBV isolate IS/1366	н					V						v		Y							v		Q									S			т					
13. IBV isolate IS/236	R	v	v	Ν		S		1						S	s			A			S		Q					Y				S		т	т					
14. IBV isolate IS/1494/06	١.					S								D	т						А		Q												т					
15. IBV strain H120	N	S	v	N	т	т	F	т	F	т	÷.	s	Ĺ.			D	w	R	Q	P	к			w		?	R	i.	F	ĸ	L		ĸ	н	ĸ	Q	L	R	v	?
16. IBV strain Ma5	R	v	v	Ν		s		1						s	s			Α			s		Q					Y				s		т	т					
17. IBV strain Connecticut 46	м	G	L	F		т			v	1	v	L	?		к	D		Е	L	L	Ν	F	Y	s	s		к	Ρ	s	G		Ν	ĸ		L		1	L	А	R
18. IBV strain 4/91	Y		1									v		Р	Α						v		Q									s			т					
19. IBV strain D41	R	v	v	Ν		s		1						s	s			А			Ν		Q					Y				s		т	т					
									5	50									(	60										70									4	80
Name	С	Y	К	S	G	S	С	Ρ	L	т	G	М	1	Ρ	Q	N	Y	I.	R	L	S	A	М	R	N	N	S	L	F	Y	N	L	т	٧	A	٧	т	к	Y	S
1. IBV isolate Ismailia Egy/2014	Γ.																																							Ξ.
2. IBV isolate Eg/12197B/2012																																			s					
3 IBV isolate CU-2																																								
4 IBV isolate Eg/12120s/2012																Ĥ.																								
5 IBV/Egypt/01-13//IR9715/2012	, ·			v								1		1			1		1				1		1		i.													
6 IBV isolate RE/06/2008	1			Ĥ								i.												ĸ		ŝ														P
7 IBV isolate RF/07/2008	11			н								ĩ					Ĥ.						1	ĸ	1	s														P
8 IBV virus (IBV) (UK/142/86)				н		Ē						ĩ												ĸ		ŝ														P
9 IBV (IK(123/82)												ĩ	-			Ŷ	ĥ.							ĸ	1	ŝ														P
10 IBV strain IS/589/98	11											ĩ					н							ĸ	1	ŝ														P
11 IBV strain IS/572/98	11											ĩ					н		1					ĸ	1	ŝ														P
12 IBV isolate IS/1388		÷.		ù.												ù.	н								'n i	Ğ	v.								ŝ		ŝ			P
13 IBV isolate IS/236				ü	v	Ġ			÷				÷.	ò		Π.	e			ý.				ĸ.	× 1	š	ò								ě		Ā			b
14 IBV isolate IS/200						0		ė				÷.		~			ŭ		1	•			1	2	1	e	4								0		^			6
16 IBV strain H120	÷.		Å.	-	Å.	ė	ė	5		è	ė	č	ŵ.	4	ė		5	÷.	÷.	ċ		÷	ù.	D	è	~	ñ.	2	2	'n.	4	2		÷	Ň	Ň.	ċ	÷		-
16 IBV strain Ma5	11			5		6	9	ſ	÷	3	3		ĩ.	0	9	ù.	e	Tel:		v				ĸ	٠	š	8	1	1	0		ŕ		1	0		~		**	P
17 IDV strain Connecticut 40													s.,	-14			9			۰.				• •			14								9		0		2	5
	D.	F		F	C		H.		2	8	\$	т	т	2	R	9	E		E	D.			E	т	Q 1	V	N			D	v	2		D	F	Δ	~		ĸ	
18 IBV strain Connecticut 40	D	F		F	С		н	L	?	s	S	т	т	?	R	s	F		Е	D	L	L	F	Т	S	V	N E		L	D	Y	?		D	E	A	Y		ĸ	P
17. IBV strain Connecticut 46 18. IBV strain 4/91 19. IBV strain D41	D	F		F Q O	с		H	L	?	S	S	Ţ	T	?	R	S	FH		E	D	L ·	L ·	F	K	S S	G	F		Ļ	D	Y	?		D	E S s	A	Y S		ĸ	P

									9	0									10	0								1	10	
Name	F	K	S	L	Q	С	۷	Ν	Ν	М	T :	s١	1	( )	. N	G	D	L	٧	F	Т	S	Ν	D	Т	Q	D	V I	S A	A
1. IBV isolate Ismailia Egy/2014																														
2. IBV isolate Eg/12197B/2012																														
3. IBV isolate CU-2																														
4. IBV isolate Eg/12120s/2012																														
5. IBV/Egypt/01-13/VIR9715/2012																														
6. IBV isolate RF/06/2008																								Е		к				
7. IBV isolate RF/07/2008																								Е		к				
8. IBV virus (IBV) (UK/142/86)																								E		к				
9. IBV (UK/123/82)																								E		к				
10. IBV strain IS/589/98										Ĺ.																К				
11. IBV strain IS/572/98										Ē.																к				
12. IBV isolate IS/1366			т	F				S		s					1									E		s	Y		T C	
13. IBV isolate IS/236				F						Ē.										Y				E		Ť		1	T S	
14. IBV isolate IS/1494/06												A														ĸ				
15. IBV strain H120	s	Ĺ.		v.	s	i.	A	Ŷ	G	P	o i	G		i i	c c	s	v	F	s	Q	P	v	v	Ň	Ĺ.	т	Ĥ I	Ň I	E V	ιì.
16. IBV strain Ma5				F						È.										Y				A		Ť		. 1	T S	
17. IBV strain Connecticut 46	Å	Ġ	P	2	R	È.	P	÷	G	P	Â	ċ,	F	ε e	Y	Ň	Ġ			i.	P	P	÷.	ï		Å	Ê I	й (	άт	÷È.
18 IBV strain 4/91		ĩ				-		G		s											1		1	E		т	н		r c	
19. IBV strain D41				F				Ĩ		ĩ										Ŷ				E		Ť		1	T S	
THE PERSON AND A P										-																			e	e

**Fig 10**: Deduced amino acid of different Egyptian IBV variant strains compared with other Egyptian and Israeli variants. Dots indicate identical sequences.



Fig 11: Phylogenetic tree based on a partial sequence of the S1 gene, showing the relationship between different IBV isolates. The robustness of individual nodes of the tree was assessed using 1000 replications of bootstrap re-sampling of the originally aligned nucleotide sequences.

		IBV_isolate_Isma	ilia_Egy/2012		
		Nucleotides (342)		Amino acids (114)	
		Identity No. (%)	Divergence	Identity	Divergence
			No. (%)	No. (%)	No. (%)
1-	Eg/12197B/2012	340 (99.41%)	2 (0.59%)	113 (99.12%)	1 (0.88%)
2-	Eg/CU-2/2012	339 (99.12%)	3 (0.88%)	114 (100)	0 (0%)
3-	Eg/12120s/2012	338 (98.83%)	4 (1.17%)	113 (99.12%)	1 (0.88%)
4-	Egypt/01-	337 (98.54%)	5 (1.46%)	112 (98.25%)	2 (1.75%)
	13/VIR9715/2012				
5-	RF/06/2008	318 (92.98%)	24 (7.02%)	104(91.23%)	10 (8.77%)
6-	RF/07/2008	318 (92.98%)	24 (7.02%)	104 (91.23%)	10 (8.77%)
7-	UK/142/86	318 (92.98%)	24(7.02%)	105(92.10%)	9 (7.90%)
8-	UK/123/82	319 (93.27%)	23 (6.73%)	103 (90.35%)	11 (9.65%)
9-	IS/589/98	303 (88.60%)	39 (11.40%)	101 (88.60%)	13 11.40%)
10-	IS/572/98	303 (88.60%)	39 (11.40%)	101 (88.60%)	13 11.40%)
11-	IS/1366-Sp1	263 (76.90%)	79 (23.10%)	86 (75.44%)	28 (24.56%)
12-	IS/236-S1	248 (72.51%)	94 (27.49%)	76 (66.67%)	38 (33.33%)
13-	IS-1494	297 (86.84%)	45 (13.16%)	99 (86.84%)	15 (13.16%)
14-	4/91	260 (76.02%)	82 (23.89%)	88 (77.20%)	26 (22.80%)
15-	H120	132 (38.60%)	210(61.40%)	20 (17.54%)	94 (82.45%)
16-	Ma5	247 (72.22%)	95 (27.78%)	76 (66.67%)	38 (33.33%)
17-	Connecticut	162 (47.37%)	180(52.63%)	22 (19.30%)	92 (80.70%)
18-	D41	246 (71.93%)	96 (28.07%)	76 (66.67%)	38 (33.33%)

 Table 1: Nucleotides and amino acids identity and divergence of IBV\_isolate\_Ismailia\_Egy/2012 compared with theIBV sequences in GenBank database:

**Conclusion**: IBV Ismailia isolates are closely related to the recent Egyptian IBV isolates circulating in Egypt except minor changes in nucleotides and amino acids. IBV Ismailia isolates are different from the currently IB virus strains used for vaccine production, indicating a constant evolution of IBV in Egypt. This difference necessitates continuous monitoring to control the spread of infections and the development and use of vaccine should be based on indigenous viruses.

#### Acknowledgment

The authors are highly grateful for Dr. Mohammed Fawzy, lecturer of virology, Faculty of Veterinary Medicine in Ismailia, for his great help during performance of the investigations of this work.

#### References

Abdel-Moneim A, Manal, A. Afifi and Magdy F. El-Kady. (2012): Emergence of a novel genotype of avian infectious bronchitis virus in Egypt Arch Virol (2012) 157:2453– 2457.

Abdel-Moneim, A., El-Kady, M., Ladman, B.S., Gelb, J., (2006): S1 gene sequence analysis of a nephropathogenic strain of avian infectious bronchitis virus in Egypt. Virol. J. 3, 78.

Adzhar, A., Gough, R. E., Haydon, D., Shaw, K., Britton, P. & Cavanagh, D. (1997): Molecular analysis of the 793/B serotype of infectious bronchitis virus in Great Britain. Avian Pathology 26, 625.

Albassam MA, Winterfield RW, Thacker HL (1986): Comparison of the nephropathogenicity of four strains of infectious bronchitis virus. Avian Dis 30:468-476.

Alexander, D.J, Gough, R. E and Pattison, M.(1978): A long term study of the pathogenesis of infection of fouls with three strains of avian infectious bronchitis virus.

Bayry, G.; Mallikarjun S. G.; Prashant K. N.; Supriya G. K.; Brian S. L.; Jack Gelb, Jr.; Govind R. G. and Gopal N. K. (2005): Emergence of a Nephropathogenic Avian Infectious Bronchitis Virus with a Novel Genotype in India J. Clinical Microbiol, 2 : 916–918.

Benyeda ,z., Mato,T., Suveges,T., Szabo,E., Kardi, V., Abonyi,Toth,Z.mRusvai,

**M.,Paly,V.(2009):** Comparison of the pathogenicity of QX like M4 and 793/B infectious bronchitis strains from different pathological conditions. Avian pathology. 38, 449-456.

Benyeda, Z., Szeredi, L., Mato, T., Suveges, Balka, G., Т., Abonyi-Toth, Z., Rusvai. М., Palya, V.(2010): Comparative histopathology and immunohistochemistry of qx- like Massachusetts and 793/B serotypes infectious bronchitis of virus infection in chickens. Comp Pathol. 143.276-83.

Boroomand. Z., Asasi. K., Mohammadi. A. (2012):Pathogenesis and tissue distribution of avian infectious bronchitis virus isolate IRFIBV 32 (793/B serotype) in experimentally infected broiler chickens "Scientific world Journal. 402537.

**Calnek, B. W., (1997):** Diseases of Poultry, 10th edn. Iowa State University Press, Ames, IO.

Capua, I., Gough, R.E., Mancini, M., Casaccia, C., Weiss, C., (1994): A 'novel' infectious bronchitis strain infecting broiler chickens in Italy. J. Vet.Med. B 41, 83–89.

Cavanagh D, Davis PJ, Cook JKA, Li D, Kant A, Koch G (1992): Location of the amino-acid differences in the S1 spike glycoprotein subunit of closely related serotypes of infectious bron-chitis virus. Avian Pathol 21:33–43.

Cavanagh D, Davis PJ, Pappin DJ, Binns MM, Boursnell ME, Brown TD (1986): Coronavirus IBV: partial amino terminal sequencing of spike polypeptide S2 identifies the sequence Arg-Arg-Phe-Arg-Arg at the cleavage site of the spike precursor propolypeptide of IBV strains Beaudette and M41.Virus Res, 4, 133–143.

Cavanagh, D., and P. J. Davis, (1986): Coronavirus IBV: removal of spike glycopolypeptide S1 by urea abolishes infectivity and haemagglutination but not attachment to cells. J. Gen. Virol. 67, 1443–1448. **Cavanagh, D. (1983):** Coronavirus IBV: structural characterization of the spike protein. J. Gen. Virol. 64:2577–2583.

Cavanagh, D. (1995): The coronavirus surface glycoprotein. In: The coronaviruses. Ed. S.G.Siddell, Plenum Press, New York. pp 73-113.

Cavanagh, D., **P.J.** Davis, Mockett. and A.P.A., (1988): Amino acids within hypervariable region 1 of avian coronavirus IBV (Massachusetts serotype) spike glycoprotein are associated with neutralization epi-topes. Virus Res. 11, 141–150.

Cavanagh, D., Naqi, S., (2003): Infectious bronchitis. In: barnes, H.J. Fadly, A. M. Glisson, F. J. R., McDougald, L. R., Swayne, D. E. (Eds), Diseases of poultry. 11<sup>th</sup> edn. Iowa State University Press, Ames, PP. 101-119.

Cavanagh, D., Picault, J. P., Gough, R. E., Hess, M., Mawditt, K., Britton, P., (2005): Variation in the spike protein of the 793/ B type of infectious bronchitis virus in the field and during alternate passage in chickens and embryonated eggs. Avian pathol. 34, 20-25.

Darbyshire, J. R. (1981): Immunity to avian infectious bronchitis virus. In Avian Immunology pp 205-226 Edited by M. E. Rose, L. N. Payne, B. M. Free man. Edinburg: British poultry science.

**Davelaar, F. G., Kouwenhoven, B.** and Burage, A. G. (1984): Occurrence and significance of infectious bronchitis virus variant strains in egg and broiler production in the Netherlands. Veternary Quarterly, 6, 114-120.

De wit, S. J. J., Cook, J. K. and Vander Hechjden, H. M. (2011): Infectious bronchitis: a review of the history, current situation and control measures. Avian pathology. 40(3), 223-35.

Dolz, R., Pujols, J., Ordonez, G., Porta, R. & Majo, N. (2006): Antigenic and molecular characterization of isolates of the Italy 02 infectious bronchitis virus genotype. Avian Pathology, 35, 77-85.

**Duff RH, Macdonald JW, Mcmartin DA, Ross JG. (1971):** Veterinary record, 88: 315. Doi :10.1136/ vr 88.12.315

Gelb, J., and Wolff, J.B. & Moran, C.A. (1991): Variant serotypes of infectious bronchitis virus isolated from commercial layer and broiler chickens. Avian Diseases, 35, 82-87.

Gorgyo,M.; Umemura, T. and Itakura, C.(1984): Concurrence of nephrosis-nephritis due to infectious Bronchitis virus and infectious bursal disease in Broiler chickens Avian Pathology, 13, 191-200, 1984.

Ignjatovic, J., Ashton, D.F., Reece, R., Scott, and P. & Hooper, P. (2002): Pathogenicity of Australian strains of avian infectious bronchitis virus. Journal of Comparative Pathology, 126, 115-123. Jackwood MW, Hall D, and Handel, A. (2012): Molecular evolution and emergence of avian gammacoronaviruses. Infect Genet Evol 12(6):1305–1311

Janse, E. M., Van Roozelaar, D., and Koch, G. (1994): Leukocyte subpopulations in kidney and trachea of chickens infected with infectious bronchitis virus. Avian Pathol 23-3: 513-23.

Jia, W., Karaca, K., Parrish, C.R. & Naqi, S.A. (1995): A novel variant of avian infectious bronchitis virus resulting from recombination among three different strains. Archives of virol, 140:259-271.

Kant A, Koch G, van Roozelaar DJ, Kusters JG, Poelwik FA, van der Zeijst BA (1992): Location of antigenic sites defined by neutralizing monoclonal antibodies on the S1 avian infectious bronchitis virus glycopolypeptide. J Gen Virol 73:591–596

Keeler CL, Reed KL, Nix WA, Gelb J Jr (1998): Serotype identification of avian infectious bronchitis virus by RT-PCR of the peplomer (S-1) gene. Avian Dis 42:275–284

Kingham BF, Keeler CL, Nix WA, Ladman BS, Gelb J Jr (2000): Identification of avian infectious bronchitis virus by direct auto-mated cycle sequencing of the S-1 gene. Avian Dis 44:325–335.

Koch, G., Hartog, L., Grant, A., VanRoozelaar, and D.J., (1990): Antigenic domains on the peplomer protein of avian infectious bronchitis virus: correla-tion with biological functions. J. Gen. Virol. 71, 1929–1935.

Lee, S.K., Sung, H.W. & Kwon, H.M. (2004)]: S1 glycoprotein gene analysis of infectious bronchitis viruses isolated in Korea. Archives of Virology, 149, 481-494.

**Luna, L (1988):** Manual of histologic staining methods of the Armed Forced Institute of Pathology. 3<sup>rd</sup> ed. McGraw Hill book company, New York.

Meir, R., Rosenblut, E., Perl, S., Kass, N., Ayali, G., Perk, S. & Hemsani, E. (2004): Identification of a novel nephropathogenic infectious bronchitis virus in Israel. AvianDis.48, 635-641.

Momayez, R., Pourbakhsh, S.A., Khodashenas, M., Banani, M., (2002): Isolation and identification of Infectious bronchitis virus from commer-cial chickens. Arch. Razi Inst. 53, 1–9.

Moore KM, Jackwood MW, Hilt DA (1997): Identification of amino acids involved in a serotype and neutralization specific epitope within the S1 subunit of avian infectious bronchitis virus. Arch Virol 142:2249–2256.

Owen R. L, Cowen, B. S., Hattel, A. L., Naqi, S.A. Wilson, R. A. (1991): Detection of viral antigen following exposure of one- day-old chickens to the Holland 52 strain of infectious bronchitis virus. Avian Pathol. Dec, 20(4): 663-73.

Peyman, B., Momeyz, R., Mohamed, H., Bozorgmen farid, Mohamed, H. and Sayed, A.P. (2013): Experimental study on histopathological changes and tissue tropism of Iranian infectious bronchitis serotype 793/ Blike virus in SPF chickens.J. Of the South African Veterinary association 84(1), 970.

**Purcell D. A. and McFerran, J. B.** (1972): "The histopathology of infectious bronchitis in the domestic fowl,"Research in Veterinary Science, vol. 13, no. 2, pp. 116–122.

**Purcell DA, Tham VL, Surman PG (1976):** The histopathology of infectious bronchitis in fowls infected with a nephrotropic T strain of virus. Aus Vet J, 52:85-91.

Sultan H.A.; Tantawi, L; Youseif AI and Ahmed, A.A.S. (2004):

Uroli-thiathis in white commercial egg laying chickens associated with an infectious bronchitis virus. 6th Sci Conf Egyp Vet Poult Assoc pp 155–169.

Susan, S., El-Mahdy, El-Hady, M.M. (2010): Isolation and Characterization of Nephropathogenic of Strain Infectious Bronchitis Virus in EGYPT journal of American Science 2010; 6(9):669-675]. (ISSN: 1545-1003).

Zhou, J. Y., and Y. Q. He, (2000): Cloning and sequence analysis of S1 gene of isolate J of avian nephropathogenic infectious bronchitis. J. Zhejiang Uni. (Agri. Life Sci.) 26, 369–373.

#### الملخص العربي

ظهور طفره كلويه من فيروس الالتهاب الشعبي المعدي قادره على الهروب من المناعه في الدجاج المحصن باللقاح الواقي في الاسماعليه مصر

2 محدد الشهيدى ، 1 نيفين رمزى ، 3 حمدى فتيح

<sup>1</sup> معهد بحوث صحة الحيوان بالدقى ، فرع الإسماعيلية <sup>2</sup> قسم الفير ولوجيا ، كلية الطب البيطرى، جامعة قناة السويس<sup>3</sup> قسم الباثولوجيا ، كلية الطب البيطرى، جامعة قناة السويس

على الرغم من التحصين الدوري و المنتظم لقطعان الدواجن فى مصر باللقاح الواقى لفيروس الإلتهاب الشعبى المعدى إلا أنه قد يظهر فى بعض القطعان المحصنه أعراض تنفسيه كلويه مشابهه لأعراض مرض الإلتهاب الشعبى المعدى. تم فحص عدد ٦ قطعان من الدواجن المصابه فى محافظه الإسماعيليه يحتوي كل قطيع على ٥٠٠٠ كتكوت وذلك لعزل فيروس الإلتهاب الشعبى المعدى على بيض الدجاج المخصب الخالى من المسببات المرضيه وقد تم عزل عدد ٤ معزولات فيروسيه وتم التعرف عليهم وتوصيفهم بواسطه الطرق البيولوجيه والجزيئيه المختلفة ودراسة الاثر المرضى على الأنسجة لها فى الطيور المصابة بالفحص الهستوباثولوجى، وقد تم تكبير الجين الخاص بالزوائد الفيروسيه على غلاف الفيروس المعزول بواسطه إختبار تفاعل البلمره المتسلسل المسبوق بالنسخ العكسى وتحليل تتابع القواعد النيتروجينيه فى المنطقة الأكثر تنوعاً فى هذا الجين بإستخدام بوادئ خاصه بهذا الجين وقد أثبتت النتائج أن هذا الجين قد أعطى خلوط بيضاء معري باستخدام بوادئ نيتروجينيه مزدوجه عند سريانه على الجيل بجهاز الفصل الكهربائى.

وعند تأسيس شجره العائله الوراثيه لمعزوله فيروس الإلتهاب الشعبي المعدي الإسماعيليه وجد أنه قد صنف وراثيا ضمن مجموعه فيروسات تحتوي علي أربعه فيروسات مصريه أخرى متوطنه في مصر منذ عام ٢٠١٢ وهم مصر ٢٠١٢-٢٠١٢ و مصر سي يو٢-٢٠١٢ و مصر ٢٠١٢-٢٠١٢ ومصر ٢٠-١٣ في اي ار ٢٠١٢ . وقد لوحظ أن معزوله الإسماعيليه نتشابه تماما مع العزلات المصريه الأربعه على مستوي القواعد النيتروجينيه بنسبة & %102 & %99.41 %98.54 %98.83 وتتشابه أيضاً على مستوى الأحماض الأمينيه بنسبه & %100 %99.12

**الخلاصه**: نستنتج أن فيروس الإلتهاب الشعبى المعدى المعزول من الإسماعيليه متطابق الى حد كبير مع المعزولات المصريه الأربعه المتوطنه فى مصر منذ ٢٠١٢ بإستثناء بعض الإختلافات فى بعض القواعد والأحماض الأمينيه ومختلفه تماماً عن فيروسات الإلتهاب الشعبى المعدى المستخدمه فى تحضير اللقاح الواقى فى مصر وتشير أيضاً النتائج إلى أن فيروس الإلتهاب الشعبى المعدى فى تطور مستمر ويتطلب فحصه وراثياً حتى نتم التمكن من السيطره على المرض وعدم إنتشار العدوى به وكذلك تصنيع وتطوير لقاحات جديده من المعزولات المحليه للفيروس .